GPR110 overexpression increases tumorigenic potential of HER2+breast cancer cells

被引：1
|
作者：
Trivedi, M. V.
Bhat, R.
Yadav, V.
Yadav, P.
Ai-Rawi, A.
Christiny, P.
Nanda, S.
Giuliano, M.
Creighton, C.
Osborne, C. K.
Narkar, V. A.
Schiff, R.
机构：
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
[2] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dan L Duncan Canc Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Univ Texas Houston, Inst Mol Med, Ctr Metab & Degenerat Dis, Houston, TX USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-P6-04-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-04-05
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2+breast cancer
    Said, Badr Id
    Chen, Hanbo
    Jerzak, Katarzyna J.
    Warner, Ellen
    Myrehaug, Sten
    Tseng, Chia-Lin
    Detsky, Jay
    Husain, Zain
    Sahgal, Arjun
    Soliman, Hany
    JOURNAL OF NEURO-ONCOLOGY, 2022, 159 (01) : 177 - 183
  • [32] Investigating the mechanisms of HER2+breast cancer cell redirection
    Campbell, Caroline J.
    Booth, Brian W.
    CANCER RESEARCH, 2022, 82 (12)
  • [33] A predictor of response in HER2+breast cancer-at last!
    Badve, Sunil S.
    Gokmen-Polar, Yesim
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022,
  • [34] Targeting glucose metabolism in HER2+breast cancer.
    Chang, Simone
    Chesney, Jason
    Trent, John O.
    Telang, Sucheta
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Key Genes and Prognostic Analysis in HER2+Breast Cancer
    Weng, Yujie
    Liang, Wei
    Ji, Yucheng
    Li, Zhongxian
    Jia, Rong
    Liang, Ying
    Ning, Pengfei
    Xu, Yingqi
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [36] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Estimating costs of relapsing HER2+breast cancer in Spain
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    CANCER RESEARCH, 2017, 77
  • [38] TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER
    Santamaria Elena, Capilla
    Garcia Beatriz, Benitez
    Jose Antonio, Romero Garrido
    Aunon Pilar, Zamora
    Abad Gema, Casado
    del Valle Luis, Gonzalez
    Ambrosio Alicia, Herrero
    ATENCION FARMACEUTICA, 2013, 15 (04): : 261 - 267
  • [39] Assessing Neurohormonal in HER2+Breast Cancer Patients With CTRCD
    Albulushi, Arif
    Al-Farhan, Hatem
    JACC: CARDIOONCOLOGY, 2024, 6 (04): : 625 - 626
  • [40] Scope of cell cycle inhibition in HER2+breast cancer
    Koirala, Nischal
    Aske, Jennifer
    Lin, Xiaoqian
    Dey, Nandini
    De, Pradip
    CANCER RESEARCH, 2022, 82 (12)
12345